Myostatin Neutralization Results in Preservation of Muscle Mass and Strength in Preclinical Models of Tumor-Induced Muscle Wasting - Smith, Rosamund C.; Cramer, Martin S.; Mitchell, Pamela J.; Capen, Andrew; Huber, Lysiane; Wang, Rong; Myers, Laura; Jones, Bryan E.; Eastwood, Brian J.; Ballard, Darryl; Hanson, Jeff; Credille, Kelly M.; et al. (Molecular cancer therapeutics, 2015)
Keywords: Animals; Antibodies, Neutralizing - immunology; Antibodies, Neutralizing - pharmacology; Antibody Affinity - immunology; Body Weight - drug effects; Cell Line, Tumor; Drug Evaluation, Preclinical; Female; HEK293 Cells; Humans; Male; Mice, Inbred BALB C; Mice, SCID; Muscle Strength - drug effects; Muscle, Skeletal - drug effects; Muscle, Skeletal - pathology; Muscle, Skeletal - physiopathology; Myofibrils - drug effects; Myostatin - immunology; Neoplasms - complications; Neoplasms - drug therapy; Neoplasms, Experimental - complications; Neoplasms, Experimental - drug therapy; Transplantation, Heterologous; Treatment Outcome; Wasting Syndrome - drug therapy; Wasting Syndrome - etiology